Patients with second primary cancer, except:adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumor curatively treated with no evidence of disease for <= 5 years.
Has known active central nervous system(CNS) metastases
Has an active infection requiring systemic therapy
Pregnancy or breast feeding
Patients with cardiac problem
Any previous treatment with sunitinib

NCT02691793_exc_T1
Qualifier
second
NCT02691793_exc_T2
Condition
primary cancer,
NCT02691793_exc_T3
Negation
except
NCT02691793_exc_T4
Condition
non-melanoma skin cancer
NCT02691793_exc_T5
Condition
in-situ cancer of the cervix
NCT02691793_exc_T6
Condition
solid tumor
NCT02691793_exc_T8
Mood
treated
NCT02691793_exc_T9
Mood
treated
NCT02691793_exc_T10
Scope
treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix
NCT02691793_exc_T11
Condition
metastases
NCT02691793_exc_T12
Qualifier
central nervous system
NCT02691793_exc_T13
Qualifier
CNS
NCT02691793_exc_T14
Condition
active infection
NCT02691793_exc_T16
Condition
cardiac problem
NCT02691793_exc_T17
Drug
sunitinib